{
  "pmcid": "PMC12035587",
  "pmid": "40099566",
  "title": "Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency",
  "overall_score": 0.4093457766373952,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 6,
        "items": [
          {
            "variant": "NUDT15*3",
            "gene": "NUDT15",
            "drug": "mercaptopurine",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "NUDT15*3",
              "Gene": "NUDT15",
              "Drug(s)": "mercaptopurine",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Case report: a South Asian female with homozygous NUDT15*3/*3 loss-of-function alleles developed severe mercaptopurine toxicity manifested by profound myelosuppression (ANC 0\u00d710^9/L, Hb 60 g/L, platelets 4\u00d710^9/L), hepatotoxicity (ALT 82 U/L, elevated ALP and bilirubin), and extensive alopecia shortly after thiopurine (mercaptopurine) initiation for APL maintenance. Mercaptopurine was discontinued and toxicity was attributed to inherited NUDT15 deficiency; TPMT was wildtype. Authors cite prior data that individuals homozygous for NUDT15*3 tolerated only ~8% of standard mercaptopurine doses before significant toxicity.",
              "Sentence": "Genotype NUDT15*3/*3 is associated with increased thiopurine-induced toxicity of mercaptopurine in patients with acute promyelocytic leukaemia as compared to patients without NUDT15 loss-of-function alleles.",
              "Alleles": "NUDT15*3/*3",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute Promyelocytic Leukemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "wild-type NUDT15",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Based on clinical features and the absence of a plausible alternative aetiology, a presumptive diagnosis of mercaptopurine toxicity was made. The patient underwent genetic testing and was found to have wildtype alleles in the thiopurine\u2010S\u2010methyltransferase (*TPMT*) gene, but homozygous loss\u2010of\u2010function alleles in the *NUDT15* gene (c.415C > T; *3/*3), resulting in complete loss of NUDT15 protein function. She was diagnosed with severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
                "We present a patient with severe myelosuppression, hepatotoxicity and alopecia following mercaptopurine initiation who was found to have homozygous *3/*3 loss\u2010of\u2010function alleles in the *NUDT15* gene.",
                "For example, a 2014 study showed that individuals homozygous for the *3 *NUDT15* mutation tolerated only 8% of the standard mercaptopurine dose prior to significant toxicity, similar to individuals who are homozygous for *TPMT* gene mutations."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "NUDT15*3",
                "variant_id": "PA166131621",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "mercaptopurine",
                "drug_id": "PA450379",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "TPMT*2",
            "gene": "TPMT",
            "drug": "thiopurines",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "TPMT*2",
              "Gene": "TPMT",
              "Drug(s)": "thiopurines",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Narrative summary: TPMT loss-of-function variants (*2, *3A, *3B, *3C) are described as causing intermediate (one variant) or poor (two variants) thiopurine metabolism, with poor metabolizers almost universally developing severe thiopurine toxicity even at 10-fold dose reductions. The article cites randomized data in 783 IBD patients showing that pretreatment TPMT genotyping with dose reduction reduced adverse hematologic events by ~10-fold compared with weight-based dosing alone in variant carriers.",
              "Sentence": "TPMT genotypes carrying two loss-of-function alleles (e.g., TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C) are associated with increased thiopurine-induced toxicity of thiopurines in people with inflammatory bowel disease and other thiopurine-treated conditions as compared to TPMT wild-type genotypes.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Inflammatory Bowel Diseases",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TPMT*1/*1 (wild-type)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Mutations in the *TPMT* gene are commonly implicated in cases of severe thiopurine toxicity. These mutations are inherited in an autosomal codominant pattern, and individuals who possess 1 loss\u2010of\u2010function allele are considered intermediate metabolizers whereas individuals who possess 2 loss\u2010of\u2010function alleles are considered poor metabolizers.[4] Poor metabolizers almost universally develop severe thiopurine toxicity even at 10\u2010fold dose reductions. Three polymorphisms (*2, *3A and *3C) account for over 90% of all intermediate and poor metabolizers in the general population, and this increases to over 95% with inclusion of a fourth variant (*3B), highlighting both the practicality and potential yield of genetic screening (Figure [2]).[5]",
                "Pretreatment *TPMT* screening is supported by randomized control data; 1 study consisting of 783 individuals with inflammatory bowel disease (IBD) showed that pretreatment *TPMT* screening compared to weight\u2010based dosing alone reduced the rate of adverse haematological events by 10\u2010fold in at\u2010risk individuals.[6]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "thiopurines",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*3A",
            "gene": "TPMT",
            "drug": "thiopurines",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "TPMT*3A",
              "Gene": "TPMT",
              "Drug(s)": "thiopurines",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Narrative summary: TPMT loss-of-function variants (*2, *3A, *3B, *3C) are described as causing intermediate (one variant) or poor (two variants) thiopurine metabolism, with poor metabolizers almost universally developing severe thiopurine toxicity even at 10-fold dose reductions. The article cites randomized data in 783 IBD patients showing that pretreatment TPMT genotyping with dose reduction reduced adverse hematologic events by ~10-fold compared with weight-based dosing alone in variant carriers.",
              "Sentence": "TPMT genotypes carrying two loss-of-function alleles (e.g., TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C) are associated with increased thiopurine-induced toxicity of thiopurines in people with inflammatory bowel disease and other thiopurine-treated conditions as compared to TPMT wild-type genotypes.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Inflammatory Bowel Diseases",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TPMT*1/*1 (wild-type)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Mutations in the *TPMT* gene are commonly implicated in cases of severe thiopurine toxicity. These mutations are inherited in an autosomal codominant pattern, and individuals who possess 1 loss\u2010of\u2010function allele are considered intermediate metabolizers whereas individuals who possess 2 loss\u2010of\u2010function alleles are considered poor metabolizers.[4] Poor metabolizers almost universally develop severe thiopurine toxicity even at 10\u2010fold dose reductions. Three polymorphisms (*2, *3A and *3C) account for over 90% of all intermediate and poor metabolizers in the general population, and this increases to over 95% with inclusion of a fourth variant (*3B), highlighting both the practicality and potential yield of genetic screening (Figure [2]).[5]",
                "Pretreatment *TPMT* screening is supported by randomized control data; 1 study consisting of 783 individuals with inflammatory bowel disease (IBD) showed that pretreatment *TPMT* screening compared to weight\u2010based dosing alone reduced the rate of adverse haematological events by 10\u2010fold in at\u2010risk individuals.[6]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "thiopurines",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*3B",
            "gene": "TPMT",
            "drug": "thiopurines",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "TPMT*3B",
              "Gene": "TPMT",
              "Drug(s)": "thiopurines",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Narrative summary: TPMT loss-of-function variants (*2, *3A, *3B, *3C) are described as causing intermediate (one variant) or poor (two variants) thiopurine metabolism, with poor metabolizers almost universally developing severe thiopurine toxicity even at 10-fold dose reductions. The article cites randomized data in 783 IBD patients showing that pretreatment TPMT genotyping with dose reduction reduced adverse hematologic events by ~10-fold compared with weight-based dosing alone in variant carriers.",
              "Sentence": "TPMT genotypes carrying two loss-of-function alleles (e.g., TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C) are associated with increased thiopurine-induced toxicity of thiopurines in people with inflammatory bowel disease and other thiopurine-treated conditions as compared to TPMT wild-type genotypes.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Inflammatory Bowel Diseases",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TPMT*1/*1 (wild-type)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Mutations in the *TPMT* gene are commonly implicated in cases of severe thiopurine toxicity. These mutations are inherited in an autosomal codominant pattern, and individuals who possess 1 loss\u2010of\u2010function allele are considered intermediate metabolizers whereas individuals who possess 2 loss\u2010of\u2010function alleles are considered poor metabolizers.[4] Poor metabolizers almost universally develop severe thiopurine toxicity even at 10\u2010fold dose reductions. Three polymorphisms (*2, *3A and *3C) account for over 90% of all intermediate and poor metabolizers in the general population, and this increases to over 95% with inclusion of a fourth variant (*3B), highlighting both the practicality and potential yield of genetic screening (Figure [2]).[5]",
                "Pretreatment *TPMT* screening is supported by randomized control data; 1 study consisting of 783 individuals with inflammatory bowel disease (IBD) showed that pretreatment *TPMT* screening compared to weight\u2010based dosing alone reduced the rate of adverse haematological events by 10\u2010fold in at\u2010risk individuals.[6]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "thiopurines",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "TPMT*3C",
            "gene": "TPMT",
            "drug": "thiopurines",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "TPMT*3C",
              "Gene": "TPMT",
              "Drug(s)": "thiopurines",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Narrative summary: TPMT loss-of-function variants (*2, *3A, *3B, *3C) are described as causing intermediate (one variant) or poor (two variants) thiopurine metabolism, with poor metabolizers almost universally developing severe thiopurine toxicity even at 10-fold dose reductions. The article cites randomized data in 783 IBD patients showing that pretreatment TPMT genotyping with dose reduction reduced adverse hematologic events by ~10-fold compared with weight-based dosing alone in variant carriers.",
              "Sentence": "TPMT genotypes carrying two loss-of-function alleles (e.g., TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C) are associated with increased thiopurine-induced toxicity of thiopurines in people with inflammatory bowel disease and other thiopurine-treated conditions as compared to TPMT wild-type genotypes.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Inflammatory Bowel Diseases",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TPMT*1/*1 (wild-type)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Mutations in the *TPMT* gene are commonly implicated in cases of severe thiopurine toxicity. These mutations are inherited in an autosomal codominant pattern, and individuals who possess 1 loss\u2010of\u2010function allele are considered intermediate metabolizers whereas individuals who possess 2 loss\u2010of\u2010function alleles are considered poor metabolizers.[4] Poor metabolizers almost universally develop severe thiopurine toxicity even at 10\u2010fold dose reductions. Three polymorphisms (*2, *3A and *3C) account for over 90% of all intermediate and poor metabolizers in the general population, and this increases to over 95% with inclusion of a fourth variant (*3B), highlighting both the practicality and potential yield of genetic screening (Figure [2]).[5]",
                "Pretreatment *TPMT* screening is supported by randomized control data; 1 study consisting of 783 individuals with inflammatory bowel disease (IBD) showed that pretreatment *TPMT* screening compared to weight\u2010based dosing alone reduced the rate of adverse haematological events by 10\u2010fold in at\u2010risk individuals.[6]"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "thiopurines",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "NUDT15*3",
            "gene": "NUDT15",
            "drug": "thiopurines",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "NUDT15*3",
              "Gene": "NUDT15",
              "Drug(s)": "thiopurines",
              "PMID": 40099566,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The discussion section summarizes pharmacoepidemiological data (citing Yang et al. 2014 and CPIC 2018) that the NUDT15*3 loss-of-function variant is a major determinant of thiopurine intolerance in Asians and Hispanics. A 2014 study showed that individuals homozygous for NUDT15*3 tolerated only 8% of the standard mercaptopurine dose prior to significant toxicity, similar to TPMT poor metabolizers.",
              "Sentence": "Genotype NUDT15*3/*3 is associated with increased thiopurine-induced toxicity of thiopurines in people with thiopurine-treated diseases as compared to NUDT15 wild-type genotypes.",
              "Alleles": "NUDT15*3/*3",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "thiopurine-induced toxicity of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Inflammatory Bowel Diseases",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "wild-type NUDT15",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Pharmacoepidemiological data suggest that the loss\u2010of\u2010function *3 *NUDT15* mutation drives thiopurine intolerance in these patient populations. For example, a 2014 study showed that individuals homozygous for the *3 *NUDT15* mutation tolerated only 8% of the standard mercaptopurine dose prior to significant toxicity, similar to individuals who are homozygous for *TPMT* gene mutations.[10]",
                "We present a case of severe thiopurine toxicity resulting in myelosuppression, hepatotoxicity and alopecia in an individual with homozygous *3/*3 loss\u2010of\u2010function alleles in the NUDT15 gene.",
                "We present a patient with severe myelosuppression, hepatotoxicity and alopecia following mercaptopurine initiation who was found to have homozygous *3/*3 loss\u2010of\u2010function alleles in the *NUDT15* gene. Inherited mutations in the *NUDT15* and *TPMT* genes can increase an individual's risk of severe adverse drug reactions to thiopurine medications."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "NUDT15*3",
                "variant_id": "PA166131621",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "thiopurines",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8323861956596375,
      "total_samples": 1,
      "ground_truth_annotations": {
        "count": 1,
        "matched_count": 1,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7994317173957824,
            "annotation": {
              "Variant/Haplotypes": "NUDT15*3",
              "Gene": "NUDT15",
              "Drug(s)": "mercaptopurine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*3/*3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "NUDT15*3",
                "prediction": "NUDT15*3/*3",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "NUDT15",
                "prediction": "NUDT15",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "mercaptopurine",
                "prediction": "mercaptopurine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3",
                "prediction": "*3/*3",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia",
                "prediction": "Side Effect:Myelosuppression, Side Effect:Hepatotoxicity, Side Effect:Alopecia",
                "score": 0.9943171739578247,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "non-carriers (wildtype NUDT15)",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7981495896975199,
      "total_samples": 1,
      "ground_truth_annotations": {
        "count": 1,
        "matched_count": 1,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7042496379683999,
            "annotation": {
              "Study Parameters ID": 1453076188,
              "Variant Annotation ID": 1453076180,
              "Study Type": "case series",
              "Study Cases": 0.0,
              "Study Controls": null,
              "Characteristics": "41-year-old South Asian female, severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Central/South Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1453076188,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1453076180,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "case series",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 0.0,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "41-year-old South Asian female, severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
                "prediction": "Case report of a 41-year-old South Asian female with high-risk acute promyelocytic leukaemia who developed severe mercaptopurine toxicity and was found homozygous for NUDT15 c.415C>T (*3/*3) with TPMT wildtype; no comparative control group or association statistics reported",
                "score": 0.9722438454627991,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": null,
                "prediction": "",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Central/South Asian",
                "prediction": "Central/South Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    }
  }
}